Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.75 USD | -2.38% | +8.08% | -43.24% |
05-14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.24% | 484M | |
+34.40% | 50.85B | |
+0.46% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.96% | 26.11B | |
-21.63% | 19.13B | |
+8.36% | 13.05B | |
+27.13% | 12.16B | |
+24.48% | 12.08B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine Secures FDA Rare Pediatric Disease Designation for EDIT-301 for Beta Thalassemia